CVS Caremark, Generation Health Name 13 Drugs As Initial Focus Of Pharmacogenomics Partnership; Outline Testing Procedure
Executive Summary
CVS Caremark, in partnership with Generation Health, announced the initial list of drugs that will be the focus of pharmacogenomic testing among clients of the pharmacy benefits manager, including six drugs dispensed through retail and mail-order pharmacies and seven distributed through specialty pharmacies
You may also be interested in...
Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates from any cause within six months of starting the drug
PBM Power Behind Pharmacogenomics: CVS Caremark Launching Program
CVS Caremark is expanding its commitment to pharmacogenomics with a new clinical and testing services program being developed in collaboration with newly-formed Generation Health, which describes itself as a genetic benefits management company
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011